Astrazeneca Pharma India is currently trading at Rs. 3552.40, up by 40.45 points or 1.15% from its previous closing of Rs. 3511.95 on the BSE.
The scrip opened at Rs. 3570.00 and has touched a high and low of Rs. 3570.00 and Rs. 3545.90 respectively.
The BSE group ‘A’ stock of face value Rs. 2 has touched a 52 week high of Rs. 3700.00 on 30-Jun-2020 and a 52 week low of Rs. 1635.30 on 23-Aug-2019.
Last one week high and low of the scrip stood at Rs. 3700.00 and Rs. 3420.00 respectively. The current market cap of the company is Rs. 8779.88 crore.
The promoters holding in the company stood at 75.00%, while Institutions and Non-Institutions held 4.88% and 20.12% respectively.
AstraZeneca Pharma India has received Import and Market permission in Form CT-20 (Marketing Authorization- Additional Indication) from the Drugs Controller General of India (DCGI) for Dapagliflozin film coated tablet 10mg.
Dapagliflozin film coated tablet 10mg is additional indication in adults for the treatment of heart failure with reduced ejection fraction. The receipt of this Import and Market permission paves way for launch of Dapagliflozin film coated tablet 10mg in India, subject to the receipt of related statutory approvals and licenses.
AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.
